AI Integration for Imaging Quality Assurance and Dose Monitoring

AI integration for platforms like Sectra Dose or Philips IntelliSpace Dose focuses on three core data surfaces: the protocol library, the dose structured report (SR), and the patient/study context from the PACS or RIS. The AI agent ingests DICOM Radiation Dose SR (RDSR) objects and compares exposure parameters (kVp, mAs, DLP, CTDIvol) against institutional protocols and historical benchmarks. It can automatically flag studies where dose exceeds pre-defined thresholds, identifies protocol deviations (e.g., incorrect body part selected), and detects subtle trends in dose creep across modalities or technologists.

Implementation typically involves a secure, event-driven pipeline. A DICOM listener or HL7 ORU trigger captures each completed study. The AI service processes the RDSR and relevant DICOM headers, runs inference against trained models for outlier detection and protocol adherence, and posts results back to the dose monitoring dashboard via a REST API. High-priority alerts can be routed to a dedicated QA worklist or sent via secure messaging to the lead technologist or physicist for immediate review, turning a retrospective monthly audit into a near-real-time corrective workflow.

Rollout requires careful governance and feedback loops. Initially, AI acts as an advisory system, surfacing potential issues for human validation. As confidence grows, it can automate the generation of corrective action reports or trigger mandatory just-in-time training modules in the learning management system (LMS). A key success factor is integrating AI findings back into the protocol management system itself, suggesting protocol optimizations based on aggregate AI analysis, thereby closing the loop from detection to prevention.

The core integration connects to the dose monitoring platform's data export or API layer—typically a DICOM Radiation Dose Structured Report (RDSR) feed from modalities or a HL7 stream from the PACS/RIS. For platforms like Sectra Dose or Philips IntelliSpace Dose, this involves subscribing to dose event data, which includes exam parameters (kVp, mAs, DLP, CTDIvol), patient demographics, and protocol names. The AI service, hosted in a secure, HIPAA-compliant environment, ingests this stream, normalizes the data, and runs it through trained models to flag studies that deviate from configured compliance rules or exhibit anomalous dose patterns indicative of protocol misapplication or equipment issues.

Flagged cases are routed through a configurable workflow. High-confidence outliers can trigger immediate alerts via the platform's native notification system (e.g., dashboard alerts, in-app messages for physicists) or integrated communication channels like Teams/Slack. Cases requiring review are pushed into a dedicated QA worklist within the dose platform, pre-populated with AI-generated findings such as "Protocol 'Adult Chest CT' used for pediatric patient" or "DLP 50% above institutional benchmark for this body part." The system can also generate periodic summary reports—aggregating compliance rates, top outlier modalities, and trend analysis—and push them to a reporting module or data lake for longitudinal tracking.

Governance is built into the data flow. All AI inferences are logged with a full audit trail, linking the original RDSR, the AI model version, inference results, and any subsequent human actions (override, confirm, escalate). This supports MIPS/ACR compliance and model performance monitoring. The rollout typically starts with a pilot on a single modality (e.g., CT), using the AI outputs to refine protocol libraries and alert thresholds in the dose platform before scaling to fluoroscopy, mammography, and interventional suites. The architecture is designed for continuous learning; anonymized, de-identified feedback on AI flags can be used to retrain models, creating a closed-loop system that improves both the AI and the underlying dose management protocols.

Integrating AI into imaging QA and dose monitoring platforms like Sectra Dose or Philips IntelliSpace Dose requires a security-first architecture. This typically involves a dedicated, on-premises or VPC-hosted inference service that pulls anonymized study metadata and dose reports via secure HL7 or REST APIs. AI models analyze protocol compliance, flag dose outliers, and generate findings, which are written back to the platform as structured DICOM-SR or JSON objects for review within the existing technologist or physicist dashboard. All data flows are encrypted in transit, access is controlled via platform RBAC, and every AI-generated finding is tagged with a full audit trail linking to the source study, model version, and inference timestamp.

A phased rollout is critical for clinical acceptance and risk management. Phase 1 often targets a single modality (e.g., CT) and a pilot group of super-user technologists, where AI flags are presented as non-interruptive insights in a separate panel. Phase 2 expands to more modalities and integrates AI alerts into the primary workflow queue, triggering automated notifications for high-confidence protocol deviations. Phase 3 introduces closed-loop automation, such as AI-suggested protocol corrections or automated generation of QA summary reports for physics review. Each phase includes a parallel validation period where AI recommendations are compared against manual audits to measure impact on dose optimization and protocol adherence rates.

Governance is established through a joint clinical-IT steering committee. This group defines the acceptable false-positive rate for alerts, approves the escalation pathways for different alert severities, and oversees a continuous feedback loop where technologist overrides or corrections are used to retrain and improve the models. Implementation partners like Inference Systems provide the necessary LLMOps tooling for model performance monitoring, drift detection, and prompt management, ensuring the AI operates within its validated clinical scope. This structured approach transforms AI from a black-box tool into a governed, auditable component of the quality management system, helping departments move from reactive, sample-based audits to continuous, AI-powered dose surveillance.